Evidence map›Paper›PMID 28800068›Full record

SynthesisInternational journal of molecular sciences2017

Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.

Pierpaolo Trimboli, Camilla Virili, Francesco Romanelli, Anna Crescenzi, Luca Giovanella

Abstract readEvaluation StudyMeta-AnalysisSystematic Review
In one paragraph

Synthesis in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Galectins for Diagnosis and Prognostic Assessment of Human Diseases: An Overview of Meta-Analyses.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Morphometric study in thyroid tumors.Experimental and therapeutic medicine · 2023
    Article
  9. Article
  10. Aging-associated genesOncology letters · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Galectins in Cancer and Translational Medicine: From Bench to Bedside.International journal of molecular sciences · 2018
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pierpaolo TrimboliDepartment of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Via Ospedale, 6500 Bellinzona, Switzerland. pierpaolo.trimboli@eoc.ch.
Camilla ViriliDepartment of Medico-surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100 Latina, Italy. camillavirili@libero.it.
Francesco RomanelliDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy. francesco.romanelli@uniroma1.it.
Anna CrescenziPathology Unit, University Hospital Campus Bio Medico, 00128 Rome, Italy. a.crescenzi@unicampus.it.
Luca GiovanellaDepartment of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Via Ospedale, 6500 Bellinzona, Switzerland. luca.giovanella@eoc.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The literature on Galectin-3 (Gal-3) was systematically reviewed to achieve more robust information on its histologic reliability in identifying thyroid cancers and on the concordance between Gal-3 test in histologic and cytologic samples. A computer search of the PubMed and Scopus databases was conducted by combinations of the terms thyroid and Gal-3. Initially, 545 articles were found and, after their critical review, 52 original papers were finally included. They reported 8172 nodules with histologic evaluation of Gal-3, of which 358 with also preoperative FNAC Gal-3 assessment. At histology, Gal-3 sensitivity was 87% (95% confidence intervals [CI] from 86% to 88%), and specificity 87% (95% CI from 86% to 88%); in both cases, we found heterogeneity (I₂ 85% and 93%, respectively) and significant publication bias (

Indexed as

Biomarkers, TumorCarcinomaGalectin 3HumansThyroid NeoplasmsBiomarkers, TumorGalectin 3cytologyfine needle aspiration (FNAC)Galectin-3meta-analysisthyroid cancer

Identifiers

PMID28800068
PMCPMC5578146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.